Future of epigenetic immunotherapy in kidney cancer

Cover Page

Cite item

Full Text

Abstract

In clinical practice, immune checkpoint inhibition based on the use of antibodies against PD-1 (programmed death 1), PD-L1 (programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) is actively used for treatment of kidney cancer. However, objective response to monotherapy with these drugs is observed only in 9–24 % of patients, and combinations with other anticancer drugs in most cases cause severe adverse reactions. At the same time, there is an increased risk of toxic liver damage, immune-dependent pneumonitis, and rash. Therefore, it is necessary to search for new methods of immunotherapy, the most promising of which is the method of viral mimicry based on epigenetic stimulation of retroelement expression. Double-stranded retroelement transcripts activate antiviral interferon response that induces apoptosis of tumor cells. To achieve this, inhibitors of DNA methyltransferase, deacetylase and histone methyltransferase are used which have been successfully applied to treat various malignant neoplasms. In the experiment, DNA methyltransferase inhibitor 5-aza-2-deoxytidine (decitabine) effectively inhibited clear cell renal cell carcinoma cells proliferation which indicates their potential in treatment of kidney cancer. However, similarly to other neoplasms, activation of retroelements in renal cell carcinoma serves as initiator of the tumor process as it leads to increased expression of oncogenes, inactivation of tumor suppressors, and genomic instability. Therefore, the method of viral mimicry requires a differentiated approach with inhibition of retroelements involved in carcinogenesis and simultaneous stimulation of expression of retrotransposons that are not involved in the mechanisms of tumor development and have immunogenic properties. For this, microRNAs derived from transposons can be used as guides for DNA methyltransferases. An analysis of scientific literature revealed 41 such microRNAs of which decreased expression in kidney cancer was established for miR-95, -887, -652, -585, -511, -502, -495, -493, -487b, -335; increased for miR-1249, -1266, -151a, -211, -2114, -2355, -28, -3144, -340, -342, -374a, -374b, -3934, -421, -545, -576, -582, -584, -616, -769; and specific expression in different tumor subtypes for miR-708, -577, -450b, -326, -3200, -31, -224, -192, -1271. Since activation of retroelements can lead to insertions into new genome loci with formation of new mutations involved in carcinogenesis, a promising direction in integrated immunotherapy of kidney cancer is the use of reverse transcriptase inhibitors.

About the authors

R. N. Mustafin

Bashkir State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: ruji79@mail.ru
ORCID iD: 0000-0002-4091-382X
SPIN-code: 4810-2534

Rustam N. Mustafin 

3 Lenina St., Ufa 450008

Russian Federation

References

  1. Inamura K. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci 2017;18(10):2195. doi: 10.3390/ijms18102195
  2. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  3. Dabestani S., Thorstenson A., Lindblad P. et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 2016;34(8):1081–6. doi: 10.1007/s00345-016-1773-y
  4. Feng X., Zhang L., Tu W., Cang S. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: a SEER-based analysis. Medicine (Baltimore) 2019;98(31):e16684. doi: 10.1097/MD.0000000000016684
  5. Xu W., Atkins M.B., McDermott D.F. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 2020;17(3):137–50. doi: 10.1038/s41585-020-0282-3
  6. Klapper J.A., Downey S.G., Smith F.O. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113(2):293–301. doi: 10.1002/cncr.23552
  7. Janiszewska A.D., Poletajew S., Wasiutyński A. Spontaneous regression of renal cell carcinoma. Contemp Oncol 2013;17(2):123–7. doi: 10.5114/wo.2013.34613
  8. Albiges L., Powles T., Staehler M. et al. Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 2019;76(2):151–6. doi: 10.1016/j.eururo.2019.05.022
  9. Chen D.S., Mellman I. Elements of cancer immunity and the cancerimmune set point. Nature 2017;541(7637):321–30. doi: 10.1038/nature21349
  10. Yi M., Zheng X., Niu M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21(1):28. doi: 10.1186/s12943-021-01489-2
  11. Matveev V.B. Nibolumab as the new standard of metastatic kidney cancer treatment. Onkourologiya = Cancer Urology 2017;13(3):18–26. (In Russ.). doi: 10.17650/1726-9776-2017-13-3-18-26
  12. Tannir N.M.F., Arén Frontera O., Hammers H.J. et al. Thirtymonth follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2019;37(7_suppl):547. doi: 10.1200/JCO.2019.37.7_suppl.547
  13. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. doi: 10.1056/NEJMoa1816714
  14. Zhang X., Ran Y., Wang K. et al. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 2016;10:3153–61. doi: 10.2147/DDDT.S115493
  15. Xu D., Liu H., Xiang M. et al. The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: a systematic review and meta-analysis. Medicine (Baltimore) 2020;99(41):e22567. doi: 10.1097/MD.0000000000022567
  16. Tian Y., Li R., Liu Y. et al. The risk of immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an updated systematic review and meta-analysis. Front Oncol 2021;11:667650. doi: 10.3389/fonc.2021.667650
  17. Tian Y., Zhang C., Dang Q. et al. Risk of rash in PD-1 or PD-L1- related cancer clinical trials: a systematic review and meta-analysis. J Oncol 2022;2022:4976032. doi: 10.1155/2022/4976032
  18. Nie R.C., Chen G.M., Wang Y. et al. Efficacy of anti-PD-1/PD-L1 monotherapy or combinational therapy in patients aged 75 years or older: a study-level meta-analysis. Front Oncol 2021;11:538174. doi: 10.3389/fonc.2021.538174
  19. Chen R., Ishak C.A., De Carvalho D.D. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov 2021;11(11):2707–25. doi: 10.1158/2159-8290
  20. Mustafin R.N. Relationship of TP53 gene with retroelements in urogenital organs carcinogenesis. Onkourologiya = Cancer Urology 2022;18(1):136–42. (In Russ.). doi: 10.17650/1726-9776-2022-18-1-136-142
  21. Chiappinelli K.B., Strissel P.L., Desrichard A. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015;162(5):974–86. doi: 10.1016/j.cell.2015.07.011
  22. Roulois D., Loo Yau H., Singhania R. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015;162(5):961–73. doi: 10.1016/j.cell.2015.07.056
  23. Kantarjian H.M., Roboz G.J., Kropf P.L. et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol 2017;18(10):1317–26. doi: 10.1016/S1470-2045(17)30576-4
  24. hang D., Han T., Xu X., Liu Y. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma. Int J Clin Exp Pathol 2015;8(9):11140–8.
  25. Jiang J., Yi B., Ding S. et al. Demethylation drug 5-Aza-2’- deoxycytidine-induced upregulation of miR-200c inhibits the migration, invasion and epithelial-mesenchymal transition of clear cell renal cell carcinoma in vitro. Oncol Lett 2021;22(3):662. doi: 10.3892/ol.2021.12923
  26. Hoy S.M. Tazemetostat: first approval. Drugs 2020;80:513–21. doi: 10.1007/s40265-020-01288-x
  27. Deblois G., Tonekaboni S.M., Grillo G. et al. Epigenetic switchinduced viral mimicry evasion in chemotherapy-resistant breast cancer. Cancer Discov 2020;10(9):1312–29. doi: 10.1158/2159-8290.CD-19-1493
  28. Morel K.L., Sheahan A.V., Burkhart D.L. et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer 2021;2(4):444–56. doi: 10.1038/s43018-021-00185-w
  29. Topper M.J., Vaz M., Chiappinelli K.B. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 2017;171(6):1284–300. doi: 10.1016/j.cell.2017.10.022
  30. Au L., Hatipoglu E., de Massy M.R. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 2021;39(11):149–1518.e11. doi: 10.1016/j.ccell.2021.10.001
  31. Sciamanna I., Sinibaldi-Vallebona P., Serafino A., Spadafora C. LINE-1-encoded reverse Transcriptase as a target in cancer therapy. Front Biosci (Landmark Ed) 2018;23(7):1360–9. doi: 10.2741/4648
  32. Rajurkar M., Parikh A.R., Solovyov A. et al. Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer. Cancer Discov 2022;12(6):1462–81. doi: 10.1158/2159-8290.CD-21-1117
  33. Jang H.S., Shah N.M., Du A.Y. et al. Transposable elements drive widespread expression of oncogenes in human cancer. Nat Genet 2019;51:611–7. doi: 10.1038/s41588-019-0373-3
  34. Barchitta M., Quattrocchi A., Maugeri A. et al. LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis. PLoS One 2014;9(10):e109478. doi: 10.1371/journal.pone.0109478
  35. Ye D., Jiang D., Zhang X., Mao Y. Alu methylation and risk of cancer: a meta-analysis. Am J Med Sci 2020;359(5):271–80. doi: 10.1016/j.amjms.2020.03.002
  36. Rodriguez-Martin B., Alvarez E.G., Baez-Ortega A. et al. Pancancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet 2020;52:306–19. doi: 10.1038/s41588-019-0562-0
  37. Turajlic S., Litchfield K., Xu H. et al. Insertion-and-deletionderived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017;18(8):1009–21. doi: 10.1016/S1470-2045(17)30516-8
  38. Cherkasova E., Scrivani C., Doh S. et al. Detection of an immunogenic HERV-E envelope with selective expression in clear cell kidney cancer. Cancer Res 2016;76(8):2177–85. doi: 10.1158/0008-5472.CAN-15-3139
  39. Chen D., Chen W., Xu Y. et al. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet 2019;56(1):43–9. doi: 10.1136/jmedgenet-2018-105454
  40. Kraus B., Fischer K., Buchner S.M. et al. Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. PLoS One 2013;8(8):e72756. doi: 10.1371/journal.pone.0072756
  41. Cao W., Kang R., Xiang Y., Hong J. Human endogenous retroviruses in clear cell renal cell carcinoma: biological functions and clinical values. Onco Targets Ther 2020;13:7877–85. doi: 10.2147/OTT.S259534
  42. Sekeroglu Z.A., Sekeroglu V., Kucuk N. Effects of reverse transcriptase inhibitors on proliferation, apoptosis, and migration in breast carcinoma cells. Int J Toxicol 2021;40(1):52–61. doi: 10.1177/1091581820961498
  43. Hecht M., Erber S., Harrer T. et al. Efavirenz has the highest antiproliferative effect of non-nucleoside reverse transcriptase inhibitors against pancreatic cancer cells. PLoS One 2015;10(6):e0130277. doi: 10.1371/journal.pone.0130277
  44. Ly T.T.G., Yun J., Ha J. et al. Inhibitory effect of etravirine, a nonnucleoside reverse transcriptase inhibitor, via anterior gradient protein 2 homolog degradation against ovarian cancer metastasis. Int J Mol Sci 2022;23(2):944. doi: 10.3390/ijms23020944
  45. Landriscina M., Altamura S.A., Roca L. et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008;122(12):2842–50. doi: 10.1002/ijc.23197
  46. Macfarlan T.S., Gifford W.D., Agarwal S. et al. Endogenous retroviruses and neighboring genes are coordinately repressed by LSD1/KDM1A. Genes Dev 2011;25(6):594–607. doi: 10.1101/gad.2008511
  47. Harmeyer K.M., Facompre N.D., Herlyn M., Basu D. JARID1 histone demethylases: emerging targets in cancer. Trends Cancer 2017;3(10):713–25. doi: 10.1016/j.trecan.2017.08.004
  48. Piriyapongsa J., Marino-Ramirez L., Jordan I.K. Origin and evolution of human microRNAs from transposable elements. Genetics 2007;176(2):1323–37. doi: 10.1534/genetics.107.072553
  49. Filshtein T.J., Mackenzie C.O., Dale M.D. et al. Orbid: originbased identification of microRNA targets. Mobile Genetic Elements 2012;2(4):184–92. doi: 10.4161/mge.21617
  50. Tempel S., Pollet N., Tahi F. NcRNAclassifier: a tool for detection and classification of transposable element sequences in RNA hairpins. BMC Bioinformatics 2012;13:246–58. doi: 10.1186/1471-2105-13-246
  51. Qin S., Jin P., Zhou X. et al. The role of transposable elements in the origin and evolution of microRNAs in human. PLoS One 2015;10(6):e0131365. doi: 10.1371/journal.pone.0131365
  52. Wei G., Qin S., Li W. et al. MDTE DB: a database for microRNAs derived from Transposable element. IEEE/ACM Trans Comput Biol Bioinform 2016;13(6):1155–60. doi: 10.1109/TCBB.2015.2511767
  53. Lee H.E., Huh J.W., Kim H.S. Bioinformatics analysis of evolution and human disease related transposable element-derived microRNAs. Life (Basel) 2020;10(6):95. doi: 10.3390/life10060095
  54. Watcharanurak P., Mutirangura A. Human RNA-directed DNA-methylation methylates high-mobility group box 1 protein-produced DNA gaps. Epigenomics 2022;14(12):741–56. doi: 10.2217/epi-2022-0022
  55. Wong N.W., Chen Y., Chen S. et al. OncomiR: and online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics 2018;34(4):713–5. doi: 10.1093/bioinformatics/btx627

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.